Delving into the Latest Updates on Dorzolamide Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(4S,6S)-4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide, (4S,trans)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide, 4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide

+ [8]

Target

CAs

Mechanism

CAs inhibitors(Carbonic anhydrases inhibitors)

Therapeutic Areas

Eye Diseases

Active Indication

Glaucoma

Inactive Indication

Glaucoma, Open-Angle

Originator Organization

Merck & Co., Inc.

Active Organization

Santen Pharmaceutical Co., Ltd.

Inactive Organization

Merck Sharp & Dohme Corp.

Drug Highest PhaseApproved

First Approval Date

US (09 Dec 1994),

Glaucoma, Open-Angle

Regulation-

Login to view timeline

Structure

Molecular FormulaC10H16N2O4S3

InChIKeyIAVUPMFITXYVAF-XPUUQOCRSA-N

CAS Registry120279-96-1

View All Structures (2)

This study is a double-blind randomized clinical trial in Diabetic patients (type 2) over 18 years of age who have diabetic macular edema with involvement of the central 1 millimeter (central macular thickness is more than 300 μm) and BCVA 20/30 or less who visit the retina clinic of Labbafinejad Hospital Are studied. (In patients with bilateral macular edema, only one eye is included in the study.) Complete ocular examinations (including best corrected visual acuity - anterior segment - intraocular pressure - dilated pupil funduscopy with severity of diabetic retinopathy), optical coherence tomography (OCT), EDI-OCT( Enhanced Depth Imaging Optical Coherence Tomography ) - as well as Optical coherence tomography angiography (OCTA ) are performed for all patients at baseline. Blood tests are also taken from patients for fasting blood sugar and HbA1C. Patients are then randomly divided into two groups. The first group is treated with injections of 1.25 mg of intravitreal bevacizumab monthly for 3 months (months 0, 1 and 2) with topical drops of Timolol twice a day and Dorzolamide twice a day. For the second group (control group), 3 injections of 1.25 mg of intravitreal bevacizumab monthly with artificial tears (twice a day as a placebo) are prescribed. Patients in both groups are visited 1 month after the third basic intravitreal bevacizumab (IVB) injection and complete ophthalmology examinations are performed and central thickness of macula is recorded based on the patient's OCT as well as the need for IVB re-injection. EDI (Enhanced Depth Imaging)-OCT and OCTA are performed again for all patients.

Start Date06 Oct 2021

Sponsor / Collaborator

Shahid Beheshti University of Medical Sciences

IRCT20210519051344N1 / CompletedPhase 2IIT

Studying the effect of combination topical therapy using three medications (Dorzolamide drops, Ketorolac drops, Prednisolone drops) in treatment of Ivrin Gass syndrome (CME) post cataract surgery

Start Date22 Jun 2021

Sponsor / Collaborator

Tabriz University of Medical Sciences

100 Clinical Results associated with Dorzolamide Hydrochloride

Login to view more data

100 Translational Medicine associated with Dorzolamide Hydrochloride

Login to view more data

100 Patents (Medical) associated with Dorzolamide Hydrochloride

Login to view more data

1,160

Literatures (Medical) associated with Dorzolamide Hydrochloride

01 Nov 2024·BMJ Case Reports

Choroidal effusion after initiation of topical dorzolamide treatment

Article

Author: Chan, Weilin ; Chen, Peter Feng ; Fleming, Gloria P ; Wang, Derrick James

We report a case of unilateral serous choroidal effusion in a patient without prior glaucoma surgeries that developed within 1 week of starting topical dorzolamide. A Caucasian female in her 60s with a history of severe primary open-angle glaucoma in the left eye without prior glaucoma surgeries developed irritation and subsequently blurry vision in her left eye within 1 week of starting topical dorzolamide 2% in the left eye only. Funduscopic exam and B-scan ultrasound demonstrated a serous choroidal effusion in the nasal and temporal periphery. After discontinuing dorzolamide and initiating prednisolone and cycloplegic agents, the choroidal effusions fully resolved after 2 weeks, and vision returned to baseline. Choroidal effusion can occur as a result of an idiosyncratic reaction to topical dorzolamide even in patients without prior glaucoma surgeries. Immediate cessation of dorzolamide and treatment with steroid and cycloplegic agents result in good vision recovery for dorzolamide-induced choroidal effusion.

01 Nov 2024·RETINAL Cases & Brief Reports

TOPICAL CARBONIC ANHYDRASE INHIBITORS CLOSING BILATERAL SECONDARY MACULAR HOLES AND A REVIEW OF LITERATURE

Article

Author: Chan, Weng Onn ; Lee, Yong Min ; Bahrami, Bobak

Purpose:To present a rare occurrence of bilateral macular hole secondary to vitrectomy that was successfully treated with topical carbonic anhydrase inhibitors and to review the literature for this phenomenon.Methods:Monthly clinical examination and optical coherence tomography was conducted before and after eight weeks of topical 2% dorzolamide administered twice a day.Results:A 62-year-old man who had bilateral giant retinal tears which were repaired with vitrectomy subsequently presented with bilateral small macular holes of size 74 and 78 μm. The patient was trialed on 2% topical dorzolamide twice a day and reviewed monthly with optical coherence tomography scans. Macular hole closure was identified after four weeks of topical treatment.Conclusion:Clinical improvement with conservative measures suggests a potential first-line approach to the treatment of macular holes avoiding surgery and its risk profile. We also present a review of the literature regarding macular holes treated with topical carbonic anhydrase inhibitors and its mechanism of action in treating macular holes.

01 Nov 2024·Clinical & Experimental Ophthalmology

Topical dorzolamide for macular holes: A randomised, double‐blind, placebo‐controlled trial

Article

Author: Selva, Dinesh ; Baranage, Duleepa ; Durkin, Shane ; Sia, David ; Bahrami, Bobak ; Lake, Stewart ; Casson, Robert J. ; Agrawal, Surbhi ; Gilhotra, Jagjit Singh ; Bausili, Montserrat Maria ; Wong, Wilson ; Lee, Yong Min ; Chan, Weng Onn ; Sivagurunathan, Premala Devi

AbstractBackgroundTo assess topical dorzolamide as medical therapy for idiopathic full‐thickness macular holes (FTMHs).MethodsRandomised, double‐blinded, placebo‐controlled, single‐centre clinical trial involving 32 patients with idiopathic small FTMHs (<400 ). Participants in both arms used topical dorzolamide 2% or saline thrice daily for 8 weeks with monthly OCT. Those with persisting FTMH underwent vitrectomy with ILM peel and gas tamponade. The primary outcome was the rate of FTMH closure at the end of treatment.ResultsBetween 6 March 2020 and 16 June 2023, 32 eligible patients were enrolled: 16 participants in each arm. All participants in both groups were included in the final analysis. At the final visit, 3 of 16 (18.8%) patients in both the topical dorzolamide and placebo group demonstrated closure. There was no statistically significant difference in the proportion of FTMH closure between the control and treatment group (p = 1.00), nor statistically significant difference in the mean change in best corrected visual acuity (BCVA; p = 0.909). There was no difference in the change in FTMH diameter between groups (p = 0.225). No serious adverse events were reported in either group.ConclusionTopical dorzolamide was safe but not superior to placebo in the functional and anatomical outcomes of FTMH.

100 Deals associated with Dorzolamide Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00653	Dorzolamide Hydrochloride	S01EC03	DB00869

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	JP	Santen Pharmaceutical Co., Ltd.	12 Mar 1999

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


DMAC (EURETINA2024) Manual	Not Applicable	Dystrophy, Macular	32	DorzolamideDorzolamide 2%	iksshckpkl(nzlxvbhqjh) = wjtnppzmzj axmfmtmeyy (ptfhktjjxp )	Negative	19 Sep 2024
				Saline	iksshckpkl(nzlxvbhqjh) = fjkeebloho axmfmtmeyy (ptfhktjjxp )
NCT00716586 (CTgov)	Phase 4	Macular Edema	44	2% dorzolamide	plwgimwlym(mywzwajtmh) = lkfbsmnudd dbmfrkkbxw (vjefdglgud, wmnriuhdxa - oewkssuukf) View more	-	15 Oct 2021
ARVO2021	Not Applicable	Retinitis Pigmentosa	40	Topical 1.0% Dorzolamide	(exxqywcali) = fomrybxdsj ednkczuisf (zlaxnuvdpy )	-	01 Jun 2021
2018 ARVO Annual Meeting (ARVO2018)	Not Applicable	Bloodshot eye	30	Dorzolamide 2%	(qcuyhdwzfl) = wbuevyirdm wzxnfljxde (dpyhgudlqq )	-	01 Jul 2018
				Placebo	(qcuyhdwzfl) = ozvopwmveq wzxnfljxde (dpyhgudlqq )
ARVO2014	Not Applicable	Scleral Diseases	-	dorzolamide	dgacepwuvs(rujuwvoafg) = kuotikorkp djcaomjtsw (rknokbacdz ) View more	-	01 Apr 2014
ARVO2012	Not Applicable	Ocular Hypotension	-	Agomelatine	(xqasgjdgkj) = tjwvgmovob niyiznenmm (fukudwtkge, ±1.4)	Positive	01 Mar 2012
				Control (saline + 1% DMSO)	(xqasgjdgkj) = mrwfwnrxrv niyiznenmm (fukudwtkge )
ARVO2010	Not Applicable	-	-	Latanoprost monotherapy	(mvkmxnttbo) = qwfwuufplz djdbujlfbm (umwoqzwkhi ) View more	Positive	01 Apr 2010
				Latanoprost + Dorzolamide	(mvkmxnttbo) = rjnslevybp djdbujlfbm (umwoqzwkhi ) View more
ARVO2010	Not Applicable	Macular Edema	20	Topical 2% Dorzolamide	(kktrnujovv) = cadhioitpt zcuvbsufki (kwydnjlxmw )	-	01 Apr 2010
				Topical Dorzolamide	(kktrnujovv) = rkjievlwnb zcuvbsufki (kwydnjlxmw )
ARVO2006	Not Applicable	-	6	Dorzolamide	tvayylqmun(mfcuuinaat) = kglrqiopjn shnwgoubwi (jobdhafvam, 7)	-	01 May 2006